Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance

Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. G Veerababu , J Tang , R T Hoffman , M C Daniels , L F Hebert, Jr , E D Crook , R C Cooksey and D A McClai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2000-12, Vol.49 (12), p.2070-2078
Hauptverfasser: G Veerababu, J Tang, R T Hoffman, M C Daniels, L F Hebert, Jr, E D Crook, R C Cooksey, D A McClain
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2078
container_issue 12
container_start_page 2070
container_title Diabetes (New York, N.Y.)
container_volume 49
creator G Veerababu
J Tang
R T Hoffman
M C Daniels
L F Hebert, Jr
E D Crook
R C Cooksey
D A McClain
description Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. G Veerababu , J Tang , R T Hoffman , M C Daniels , L F Hebert, Jr , E D Crook , R C Cooksey and D A McClain Department of Medicine, University of Utah School of Medicine, Veterans Administration Medical Center, Salt Lake City 84132, USA. Abstract To examine the effect of increased hexosamine flux in liver, the rate-limiting enzyme in hexosamine biosynthesis (glutamine:fructose-6-phosphate amidotransferase [GFA]) was overexpressed in transgenic mice using the PEPCK promoter. Liver from random-fed transgenic mice had 1.6-fold higher GFA activity compared with nontransgenic control littermates (276 +/- 24 pmol x mg(-1) x min(-1) in transgenic mice vs. 176 +/- 18 pmol x mg(-1) x min(-1) in controls, P < 0.05) and higher levels of the hexosamine end product UDP-N-acetyl glucosamine (288 +/- 11 pmol/g in transgenic mice vs. 233 +/- 10 pmol/g in controls, P < 0.001). Younger transgenic mice compared with control mice had lower fasting serum glucose (4.8 +/- 0.5 mmol/l in transgenic mice vs. 6.5 +/- 0.8 mmol/l in controls, P < 0.05) without higher insulin levels (48.0 +/- 7.8 pmol/l in transgenic mice vs. 56.4 +/- 5.4 pmol/l in controls, P = NS); insulin levels were significantly lower in transgenic males (P < 0.05). At 6 months of age, transgenic animals had normal insulin sensitivity by the hyperinsulinemic clamp technique. Hepatic glycogen content was higher in the transgenic mice (108.6 +/- 5.2 pmol/g in transgenic mice vs. 32.8 +/- 1.3 micromol/g in controls, P < 0.01), associated with an inappropriate activation of glycogen synthase. Serum levels of free fatty acids (FFAs) and triglycerides were also elevated (FFAs, 0.67 +/- 0.03 mmol/l in transgenic mice vs. 0.14 +/- 0.01 in controls; triglycerides, 1.34 +/- 0.15 mmol/l in transgenic mice vs. 0.38 +/- 0.01 in controls, P < 0.01). Older transgenic mice became heavier than control mice and exhibited relative glucose intolerance and insulin resistance. The glucose disposal rate at 8 months of age was 154 +/- 5 mg x kg(-1) x min(-1) in transgenic mice vs. 191 +/- 6 mg x kg(-1) x min(-1) in controls (P < 0.05). We conclude that hexosamines are mediators of glucose sensing for the regulation of hepatic glycogen and lipid metabolism. Increased hexosamine flux in the liver signals a shift toward fuel storage, resulting ultim
doi_str_mv 10.2337/diabetes.49.12.2070
format Article
fullrecord <record><control><sourceid>gale_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_880127</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A68361981</galeid><sourcerecordid>A68361981</sourcerecordid><originalsourceid>FETCH-LOGICAL-c556t-7bde163939da3955524320c4e0ef958dd975cf83492d76e55fca81a2952ae5c43</originalsourceid><addsrcrecordid>eNptkt-K1DAUxoso7rr6BIIEBPFiOibp9E_2bhl0FQbmRsG7kElP20ja1CTVnbfz0TzdGR0GJrkINL_zndMvX5K8ZnTJs6z8UBu1gwhhuRJLxpeclvRJcs1EJtKMl9-fJteUMp6yUpRXyYsQflBKC9zPkyuGq6JUXCd_tr_Aw8PoIQTjBuIa0topqt4McEsaP-noAqRFOnYujJ2KQPCudtGrITTgVQBiBhI7INag1CzweNfCYDTpjQaC2pONYeZg6NSgocYme-2QISE6r1pYkG4_grdmNDX0Ri2I20Ewcb8gaqiJ6Udl_GPdpHEgEp3F5ij1MnnWKBvg1fG8Sb59-vh1_TndbO-_rO82qc7zIqblrgZWZGhOrTKR5zlfZZzqFVBoRF7VtShz3VTZSvC6LCDPG60qprjIuYJcr7Kb5N1Bd_Tu5wQhyt4EDdaqAdwUZMmxlIkKwcUBbJUFaYZm9krjr-K81g3QGPx8V1RZgTRDPL2A455t0Jf492c8IhEeYqumEGR1vzlDF5dQ7ayFFiTas96e4dkB196F4KGRoze98nvJqJwTJ_8lTq6EZFzOicOqN0dfpl0P9anmGDEE3h4BFbSyzfxqJvznqgpDWp5m7Uzb_canPjW71PUvt9DzEQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72492198</pqid></control><display><type>article</type><title>Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>G Veerababu ; J Tang ; R T Hoffman ; M C Daniels ; L F Hebert, Jr ; E D Crook ; R C Cooksey ; D A McClain</creator><creatorcontrib>G Veerababu ; J Tang ; R T Hoffman ; M C Daniels ; L F Hebert, Jr ; E D Crook ; R C Cooksey ; D A McClain</creatorcontrib><description><![CDATA[Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. G Veerababu , J Tang , R T Hoffman , M C Daniels , L F Hebert, Jr , E D Crook , R C Cooksey and D A McClain Department of Medicine, University of Utah School of Medicine, Veterans Administration Medical Center, Salt Lake City 84132, USA. Abstract To examine the effect of increased hexosamine flux in liver, the rate-limiting enzyme in hexosamine biosynthesis (glutamine:fructose-6-phosphate amidotransferase [GFA]) was overexpressed in transgenic mice using the PEPCK promoter. Liver from random-fed transgenic mice had 1.6-fold higher GFA activity compared with nontransgenic control littermates (276 +/- 24 pmol x mg(-1) x min(-1) in transgenic mice vs. 176 +/- 18 pmol x mg(-1) x min(-1) in controls, P < 0.05) and higher levels of the hexosamine end product UDP-N-acetyl glucosamine (288 +/- 11 pmol/g in transgenic mice vs. 233 +/- 10 pmol/g in controls, P < 0.001). Younger transgenic mice compared with control mice had lower fasting serum glucose (4.8 +/- 0.5 mmol/l in transgenic mice vs. 6.5 +/- 0.8 mmol/l in controls, P < 0.05) without higher insulin levels (48.0 +/- 7.8 pmol/l in transgenic mice vs. 56.4 +/- 5.4 pmol/l in controls, P = NS); insulin levels were significantly lower in transgenic males (P < 0.05). At 6 months of age, transgenic animals had normal insulin sensitivity by the hyperinsulinemic clamp technique. Hepatic glycogen content was higher in the transgenic mice (108.6 +/- 5.2 pmol/g in transgenic mice vs. 32.8 +/- 1.3 micromol/g in controls, P < 0.01), associated with an inappropriate activation of glycogen synthase. Serum levels of free fatty acids (FFAs) and triglycerides were also elevated (FFAs, 0.67 +/- 0.03 mmol/l in transgenic mice vs. 0.14 +/- 0.01 in controls; triglycerides, 1.34 +/- 0.15 mmol/l in transgenic mice vs. 0.38 +/- 0.01 in controls, P < 0.01). Older transgenic mice became heavier than control mice and exhibited relative glucose intolerance and insulin resistance. The glucose disposal rate at 8 months of age was 154 +/- 5 mg x kg(-1) x min(-1) in transgenic mice vs. 191 +/- 6 mg x kg(-1) x min(-1) in controls (P < 0.05). We conclude that hexosamines are mediators of glucose sensing for the regulation of hepatic glycogen and lipid metabolism. Increased hexosamine flux in the liver signals a shift toward fuel storage, resulting ultimately in obesity and insulin resistance.]]></description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/diabetes.49.12.2070</identifier><identifier>PMID: 11118009</identifier><identifier>CODEN: DIAEAZ</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Adenosine Triphosphate - metabolism ; Animals ; Biological and medical sciences ; Diabetes ; Diabetes research ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Fatty Acids, Nonesterified - blood ; Glucosamine - analogs &amp; derivatives ; Glucose Intolerance - blood ; Glucose Intolerance - etiology ; Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) - metabolism ; Glycogen - metabolism ; Glycogen Synthase - metabolism ; Hexosamines ; Hyperlipidemias - blood ; Hyperlipidemias - etiology ; Liver - metabolism ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic - genetics ; Obesity - etiology ; Phosphoenolpyruvate Carboxykinase (GTP) - genetics ; Phosphoenolpyruvate Carboxykinase (GTP) - metabolism ; Phosphorylases - metabolism ; Physiological aspects ; Reference Values ; Transferases ; Triglycerides - blood ; Uridine Diphosphate N-Acetylgalactosamine - metabolism</subject><ispartof>Diabetes (New York, N.Y.), 2000-12, Vol.49 (12), p.2070-2078</ispartof><rights>2001 INIST-CNRS</rights><rights>COPYRIGHT 2000 American Diabetes Association</rights><rights>COPYRIGHT 2000 American Diabetes Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c556t-7bde163939da3955524320c4e0ef958dd975cf83492d76e55fca81a2952ae5c43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=880127$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11118009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>G Veerababu</creatorcontrib><creatorcontrib>J Tang</creatorcontrib><creatorcontrib>R T Hoffman</creatorcontrib><creatorcontrib>M C Daniels</creatorcontrib><creatorcontrib>L F Hebert, Jr</creatorcontrib><creatorcontrib>E D Crook</creatorcontrib><creatorcontrib>R C Cooksey</creatorcontrib><creatorcontrib>D A McClain</creatorcontrib><title>Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance</title><title>Diabetes (New York, N.Y.)</title><addtitle>Diabetes</addtitle><description><![CDATA[Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. G Veerababu , J Tang , R T Hoffman , M C Daniels , L F Hebert, Jr , E D Crook , R C Cooksey and D A McClain Department of Medicine, University of Utah School of Medicine, Veterans Administration Medical Center, Salt Lake City 84132, USA. Abstract To examine the effect of increased hexosamine flux in liver, the rate-limiting enzyme in hexosamine biosynthesis (glutamine:fructose-6-phosphate amidotransferase [GFA]) was overexpressed in transgenic mice using the PEPCK promoter. Liver from random-fed transgenic mice had 1.6-fold higher GFA activity compared with nontransgenic control littermates (276 +/- 24 pmol x mg(-1) x min(-1) in transgenic mice vs. 176 +/- 18 pmol x mg(-1) x min(-1) in controls, P < 0.05) and higher levels of the hexosamine end product UDP-N-acetyl glucosamine (288 +/- 11 pmol/g in transgenic mice vs. 233 +/- 10 pmol/g in controls, P < 0.001). Younger transgenic mice compared with control mice had lower fasting serum glucose (4.8 +/- 0.5 mmol/l in transgenic mice vs. 6.5 +/- 0.8 mmol/l in controls, P < 0.05) without higher insulin levels (48.0 +/- 7.8 pmol/l in transgenic mice vs. 56.4 +/- 5.4 pmol/l in controls, P = NS); insulin levels were significantly lower in transgenic males (P < 0.05). At 6 months of age, transgenic animals had normal insulin sensitivity by the hyperinsulinemic clamp technique. Hepatic glycogen content was higher in the transgenic mice (108.6 +/- 5.2 pmol/g in transgenic mice vs. 32.8 +/- 1.3 micromol/g in controls, P < 0.01), associated with an inappropriate activation of glycogen synthase. Serum levels of free fatty acids (FFAs) and triglycerides were also elevated (FFAs, 0.67 +/- 0.03 mmol/l in transgenic mice vs. 0.14 +/- 0.01 in controls; triglycerides, 1.34 +/- 0.15 mmol/l in transgenic mice vs. 0.38 +/- 0.01 in controls, P < 0.01). Older transgenic mice became heavier than control mice and exhibited relative glucose intolerance and insulin resistance. The glucose disposal rate at 8 months of age was 154 +/- 5 mg x kg(-1) x min(-1) in transgenic mice vs. 191 +/- 6 mg x kg(-1) x min(-1) in controls (P < 0.05). We conclude that hexosamines are mediators of glucose sensing for the regulation of hepatic glycogen and lipid metabolism. Increased hexosamine flux in the liver signals a shift toward fuel storage, resulting ultimately in obesity and insulin resistance.]]></description><subject>Adenosine Triphosphate - metabolism</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Diabetes</subject><subject>Diabetes research</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Fatty Acids, Nonesterified - blood</subject><subject>Glucosamine - analogs &amp; derivatives</subject><subject>Glucose Intolerance - blood</subject><subject>Glucose Intolerance - etiology</subject><subject>Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) - metabolism</subject><subject>Glycogen - metabolism</subject><subject>Glycogen Synthase - metabolism</subject><subject>Hexosamines</subject><subject>Hyperlipidemias - blood</subject><subject>Hyperlipidemias - etiology</subject><subject>Liver - metabolism</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Transgenic - genetics</subject><subject>Obesity - etiology</subject><subject>Phosphoenolpyruvate Carboxykinase (GTP) - genetics</subject><subject>Phosphoenolpyruvate Carboxykinase (GTP) - metabolism</subject><subject>Phosphorylases - metabolism</subject><subject>Physiological aspects</subject><subject>Reference Values</subject><subject>Transferases</subject><subject>Triglycerides - blood</subject><subject>Uridine Diphosphate N-Acetylgalactosamine - metabolism</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkt-K1DAUxoso7rr6BIIEBPFiOibp9E_2bhl0FQbmRsG7kElP20ja1CTVnbfz0TzdGR0GJrkINL_zndMvX5K8ZnTJs6z8UBu1gwhhuRJLxpeclvRJcs1EJtKMl9-fJteUMp6yUpRXyYsQflBKC9zPkyuGq6JUXCd_tr_Aw8PoIQTjBuIa0topqt4McEsaP-noAqRFOnYujJ2KQPCudtGrITTgVQBiBhI7INag1CzweNfCYDTpjQaC2pONYeZg6NSgocYme-2QISE6r1pYkG4_grdmNDX0Ri2I20Ewcb8gaqiJ6Udl_GPdpHEgEp3F5ij1MnnWKBvg1fG8Sb59-vh1_TndbO-_rO82qc7zIqblrgZWZGhOrTKR5zlfZZzqFVBoRF7VtShz3VTZSvC6LCDPG60qprjIuYJcr7Kb5N1Bd_Tu5wQhyt4EDdaqAdwUZMmxlIkKwcUBbJUFaYZm9krjr-K81g3QGPx8V1RZgTRDPL2A455t0Jf492c8IhEeYqumEGR1vzlDF5dQ7ayFFiTas96e4dkB196F4KGRoze98nvJqJwTJ_8lTq6EZFzOicOqN0dfpl0P9anmGDEE3h4BFbSyzfxqJvznqgpDWp5m7Uzb_canPjW71PUvt9DzEQ</recordid><startdate>20001201</startdate><enddate>20001201</enddate><creator>G Veerababu</creator><creator>J Tang</creator><creator>R T Hoffman</creator><creator>M C Daniels</creator><creator>L F Hebert, Jr</creator><creator>E D Crook</creator><creator>R C Cooksey</creator><creator>D A McClain</creator><general>American Diabetes Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8GL</scope><scope>7X8</scope></search><sort><creationdate>20001201</creationdate><title>Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance</title><author>G Veerababu ; J Tang ; R T Hoffman ; M C Daniels ; L F Hebert, Jr ; E D Crook ; R C Cooksey ; D A McClain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c556t-7bde163939da3955524320c4e0ef958dd975cf83492d76e55fca81a2952ae5c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adenosine Triphosphate - metabolism</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Diabetes</topic><topic>Diabetes research</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Fatty Acids, Nonesterified - blood</topic><topic>Glucosamine - analogs &amp; derivatives</topic><topic>Glucose Intolerance - blood</topic><topic>Glucose Intolerance - etiology</topic><topic>Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) - metabolism</topic><topic>Glycogen - metabolism</topic><topic>Glycogen Synthase - metabolism</topic><topic>Hexosamines</topic><topic>Hyperlipidemias - blood</topic><topic>Hyperlipidemias - etiology</topic><topic>Liver - metabolism</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Transgenic - genetics</topic><topic>Obesity - etiology</topic><topic>Phosphoenolpyruvate Carboxykinase (GTP) - genetics</topic><topic>Phosphoenolpyruvate Carboxykinase (GTP) - metabolism</topic><topic>Phosphorylases - metabolism</topic><topic>Physiological aspects</topic><topic>Reference Values</topic><topic>Transferases</topic><topic>Triglycerides - blood</topic><topic>Uridine Diphosphate N-Acetylgalactosamine - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>G Veerababu</creatorcontrib><creatorcontrib>J Tang</creatorcontrib><creatorcontrib>R T Hoffman</creatorcontrib><creatorcontrib>M C Daniels</creatorcontrib><creatorcontrib>L F Hebert, Jr</creatorcontrib><creatorcontrib>E D Crook</creatorcontrib><creatorcontrib>R C Cooksey</creatorcontrib><creatorcontrib>D A McClain</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: High School</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>G Veerababu</au><au>J Tang</au><au>R T Hoffman</au><au>M C Daniels</au><au>L F Hebert, Jr</au><au>E D Crook</au><au>R C Cooksey</au><au>D A McClain</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><addtitle>Diabetes</addtitle><date>2000-12-01</date><risdate>2000</risdate><volume>49</volume><issue>12</issue><spage>2070</spage><epage>2078</epage><pages>2070-2078</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><coden>DIAEAZ</coden><abstract><![CDATA[Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. G Veerababu , J Tang , R T Hoffman , M C Daniels , L F Hebert, Jr , E D Crook , R C Cooksey and D A McClain Department of Medicine, University of Utah School of Medicine, Veterans Administration Medical Center, Salt Lake City 84132, USA. Abstract To examine the effect of increased hexosamine flux in liver, the rate-limiting enzyme in hexosamine biosynthesis (glutamine:fructose-6-phosphate amidotransferase [GFA]) was overexpressed in transgenic mice using the PEPCK promoter. Liver from random-fed transgenic mice had 1.6-fold higher GFA activity compared with nontransgenic control littermates (276 +/- 24 pmol x mg(-1) x min(-1) in transgenic mice vs. 176 +/- 18 pmol x mg(-1) x min(-1) in controls, P < 0.05) and higher levels of the hexosamine end product UDP-N-acetyl glucosamine (288 +/- 11 pmol/g in transgenic mice vs. 233 +/- 10 pmol/g in controls, P < 0.001). Younger transgenic mice compared with control mice had lower fasting serum glucose (4.8 +/- 0.5 mmol/l in transgenic mice vs. 6.5 +/- 0.8 mmol/l in controls, P < 0.05) without higher insulin levels (48.0 +/- 7.8 pmol/l in transgenic mice vs. 56.4 +/- 5.4 pmol/l in controls, P = NS); insulin levels were significantly lower in transgenic males (P < 0.05). At 6 months of age, transgenic animals had normal insulin sensitivity by the hyperinsulinemic clamp technique. Hepatic glycogen content was higher in the transgenic mice (108.6 +/- 5.2 pmol/g in transgenic mice vs. 32.8 +/- 1.3 micromol/g in controls, P < 0.01), associated with an inappropriate activation of glycogen synthase. Serum levels of free fatty acids (FFAs) and triglycerides were also elevated (FFAs, 0.67 +/- 0.03 mmol/l in transgenic mice vs. 0.14 +/- 0.01 in controls; triglycerides, 1.34 +/- 0.15 mmol/l in transgenic mice vs. 0.38 +/- 0.01 in controls, P < 0.01). Older transgenic mice became heavier than control mice and exhibited relative glucose intolerance and insulin resistance. The glucose disposal rate at 8 months of age was 154 +/- 5 mg x kg(-1) x min(-1) in transgenic mice vs. 191 +/- 6 mg x kg(-1) x min(-1) in controls (P < 0.05). We conclude that hexosamines are mediators of glucose sensing for the regulation of hepatic glycogen and lipid metabolism. Increased hexosamine flux in the liver signals a shift toward fuel storage, resulting ultimately in obesity and insulin resistance.]]></abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>11118009</pmid><doi>10.2337/diabetes.49.12.2070</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2000-12, Vol.49 (12), p.2070-2078
issn 0012-1797
1939-327X
language eng
recordid cdi_pascalfrancis_primary_880127
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adenosine Triphosphate - metabolism
Animals
Biological and medical sciences
Diabetes
Diabetes research
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Fatty Acids, Nonesterified - blood
Glucosamine - analogs & derivatives
Glucose Intolerance - blood
Glucose Intolerance - etiology
Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) - metabolism
Glycogen - metabolism
Glycogen Synthase - metabolism
Hexosamines
Hyperlipidemias - blood
Hyperlipidemias - etiology
Liver - metabolism
Medical sciences
Mice
Mice, Inbred C57BL
Mice, Transgenic - genetics
Obesity - etiology
Phosphoenolpyruvate Carboxykinase (GTP) - genetics
Phosphoenolpyruvate Carboxykinase (GTP) - metabolism
Phosphorylases - metabolism
Physiological aspects
Reference Values
Transferases
Triglycerides - blood
Uridine Diphosphate N-Acetylgalactosamine - metabolism
title Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T22%3A53%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overexpression%20of%20glutamine:%20fructose-6-phosphate%20amidotransferase%20in%20the%20liver%20of%20transgenic%20mice%20results%20in%20enhanced%20glycogen%20storage,%20hyperlipidemia,%20obesity,%20and%20impaired%20glucose%20tolerance&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=G%20Veerababu&rft.date=2000-12-01&rft.volume=49&rft.issue=12&rft.spage=2070&rft.epage=2078&rft.pages=2070-2078&rft.issn=0012-1797&rft.eissn=1939-327X&rft.coden=DIAEAZ&rft_id=info:doi/10.2337/diabetes.49.12.2070&rft_dat=%3Cgale_pasca%3EA68361981%3C/gale_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72492198&rft_id=info:pmid/11118009&rft_galeid=A68361981&rfr_iscdi=true